Overview
Medicofarma is a company specializing in contract manufacturing of pharmaceuticals and dietary supplements. It is the first Polish producer of a COVID-19 test, known as MediPAN-2G+ FAST COVID, which is recognized for its speed and sensitivity. The company also operates a Research and Development Laboratory to innovate in health protection and produce various pharmaceutical forms.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
Medicofarma produces the Polish MediPAN-2G+ FAST COVID test. Poland can become independent from importing foreign tests.
Medicofarma introduces the MediPAN-2G+ FAST COVID coronavirus test to the Polish market
Medicofarma to launch Real-time RT-PCR coronavirus test on the Polish market
Medicofarma produced a pilot series of the first Polish coronavirus tests
Medicofarma will produce coronavirus detection tests for Hemp&Health from NewConnect
First test differentiating COVID-19 and Flu.
Industry
Bank accounts
Registered as a VAT taxpayer on 2001-01-10. Active
22 1020 1068 0000 1902 0525 2756- 24 1020 1068 0000 1602 0525 2673
- 27 1020 1068 0000 1702 0525 2764
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
7 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Feb 29, 2016 | Commercial Companies Code notice | |
| Jun 22, 2015 | Shareholders' meeting convened | |
| Jul 31, 2014 | Commercial Companies Code notice | |
| Aug 6, 2013 | Shareholders' meeting convened | |
| Feb 8, 2013 | Shareholders' meeting convened |
Public aid
22 public aid cases recorded, with a total value of $3,337,909.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2026 | Regional investment aid | $293,105 | DRUGI MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE | |
| Jan 30, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,092 | Prezes Banku Gospodarstwa Krajowego | |
| Jan 9, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $68 | PGE Obrót S.A. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-07-01 | Wdrożenie wyników prac B+R i uruchomienie produkcji innowacyjnych dermo-kosmetyków zawierających opatentowaną cząsteczkę 4-N-furfurylocytozynę. | $1,292,712 | Program Operacyjny Inteligentny Rozwój |
Tenders
2 tenders recorded as contractor: 1 national ($33,109) and 1 EU ($215,735).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Aug 26, 2024 | Przepakowanie i zaślepienie leków z substancją czynną pirfenidon oraz nintedanib | $215,735 | Narodowy Instytut Geriatrii,Reumatologii I Rehabilitacji Im. Prof. Dr Hab. Med. Eleonory Reicher | |
| May 2, 2022 | Dostawa placebo i leku referencyjnego w związku z realizacją niekomercyjnego badania klinicznego | $33,109 | Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Each member of the management board acting independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Cezary Robert Kilczewski (61)  | Shareholder of a joint-stock company, 80.95% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| PolfarmexS.A. | $73,543,379.32 | polfarmex.pl | |
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | |
| Poznańskie Zakłady Zielarskie HerbapolS.A. | $31,668,225.77 | herbapol.poznan.pl | |
| VipharmS.A. | $30,660,173.61 | vipharm.pl | |
| Fagronsp. z o.o. | $21,715,187.73 | fagron.pl | |
| Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o. | $21,462,728.43 | farmapol.pl | |
| Przedsiębiorstwo Produkcyjno-Handlowe EwaS.A. | $14,322,437.53 | ewa-sa.pl | |
| Labofarmsp. z o.o. | $6,814,569.78 | labofarm.pl | |
| PoltregS.A. | $1,906,011.66 | poltreg.com | |
| Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o. | $1,184,204.34 | labor.com.pl |
Change history
| Date | Event |
|---|---|
| 2019-11-27 | Share capital change (20,000,000.00 PLN → 21,000,000.00 PLN) |
| 2019-08-21 | Share capital change (17,000,000.00 PLN → 20,000,000.00 PLN) |
| 2015-12-07 | Address change (Sokołowska 9/19, 01-142, Warszawa → Ul. Sokołowska 9/U19, 01-142, Warszawa) |
| 2015-12-07 | PKD change (Removed: 21, 22, 49, 52, 62, 66.11.Z, 66.19.Z, 68, 69.20.Z, 70.2, 75.00.Z, 82.92.Z; Added: 21.10.Z, 21.20.Z, 75) |
| 2013-04-12 | Share capital change (16,000,000.00 PLN → 17,000,000.00 PLN) |
FAQ
Last updated: 2026-03-22